Search Results for: EU

By Kuldip K. Ambastha (This week’s update is a follow-up to What Caught Our Attention in the Investment World? – Week of October 28-November 1, 2019.) On Wednesday, September 9, 2020, the stock of Tiffany & Co. saw a -6.4% return. Tiffany & Co. (TIF) and LVMH Moët Hennessy (LVMH) (LVMUY) were in the news …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 8-11, 2020”

By Kuldip K. Ambastha Tailored Brands, Inc. (TLRD), Seven & i Holdings Co. (SVNDY), and Marathon Petroleum Corporation (MPC) were in the news this past week. Tailored Brands owns retail fashion companies, such as Men’s Wearhouse and Jos A. Bank, and has filed for bankruptcy because of the coronavirus pandemic. The company is looking to …

Continue reading “What Caught Our Attention in the Investment World? – Week of August 3 – 7, 2020”

By Kuldip K. Ambastha Until recently, Eastman Kodak Company (KODK) had been best known for its famous camera and photography offerings from the past. The company was founded in 1888, in Rochester, New York. With the rise of new technology offerings such as sophisticated smartphone cameras, Eastman Kodak Company was not in the press as …

Continue reading “What Caught Our Attention in the Investment World? – Week of July 27 – 31, 2020”

By Kuldip K. Ambastha Jerome Powell, the Chair of the U.S. Federal Reserve, issued detailed comments this week. The American economy continues to be ravaged by the coronavirus pandemic. Additional fiscal support aid (e.g. another round of stimulus payments to Americans) will likely be needed for the American economy to recover. However, the Fed is …

Continue reading “Negative Interest Rates in the USA are Unlikely – Week of May 11 – 15, 2020”

By Kuldip K. Ambastha and Anil K. Ambastha On Friday, January 3, 2020, Tesla, Inc. (TSLA) delivered a gain of 3.0% closing at an all-time high of $443.01 per share due to positive news. Intra-day, the share price reached as high as $454.00 per share. Tesla beat Wall Street estimates for both car production and …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 30, 2019 – January 3, 2020”

By Kuldip K. Ambastha and Anil K. Ambastha On Monday, December 9, 2019, big news emerged in the mergers & acquisitions field in terms of Merck & Co., Inc. (MRK) buying ArQule, Inc. (ARQL) and Sanofi SA (SNY) buying Synthorx Inc. (THOR). Both Merck and Sanofi bought the smaller companies to enhance their capabilities in …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 9-13, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha On Thursday, December 5, 2019, there was “a tale of two cities,” to quote Charles Dickens. In the biotech arena, SAGE (Sage Therapeutics, Inc.) and AUPH (Aurinia Pharmaceuticals Inc.) were big movers. Sage Therapeutics delivered -59.7% for the day, while Aurinia Pharmaceuticals returned 78.8%. SAGE-217 is a …

Continue reading “What Caught Our Attention in the Investment World? – Week of December 2-6, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha Karuna Therapeutics Inc. (KRTX), a clinical-stage biopharmaceutical company, was founded in 2009 and is headquartered in Boston, MA. The company is focused on developing innovative therapies for individuals suffering from disabilities, disorders, and pain. Karuna Therapeutics Inc. has announced that its schizophrenia treatment’s Phase 2 clinical trial …

Continue reading “What Caught Our Attention in the Investment World? – Week of November 18-22, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha On October 22, 2019, Biogen Inc. (BIIB) delivered a 26.1% return for the day. This was the stock’s largest one-day percentage return in 23 years. Its Alzheimer’s drug (aducanumab) had previously been written off as a failure, but now will be getting a second chance at approval …

Continue reading “What Caught Our Attention in the Investment World? – Week of October 21-25, 2019”

By Kuldip K. Ambastha and Anil K. Ambastha Acadia Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company which has Nuplazid (aka: pimavanserin) in its product pipeline. Nuplazid has been used by individuals suffering from Parkinson’s disease-linked psychosis. Acadia has now analyzed Nuplazid in relation to individuals suffering from dementia-related psychosis. Currently, no approved drugs exist in …

Continue reading “What Caught Our Attention in the Investment World? – Week of September 9-13, 2019”